| Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma. | |
MedLine Citation:
|
PMID: 19661318 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
MATERIALS AND METHODS: DAN-G pancreatic carcinoma cells were treated with carboplatin and gemcitabine in vitro under hyperthermic conditions of 37 degrees C, 39 degrees C, 41.8 degrees C and 43 degrees C and cytotoxic drug effects were measured under various conditions using crystal violet assays. Data on outcome and toxicity of a clinical study using gemcitabine and carboplatin with 41.8 degrees C whole-body hyperthermia in a compassionate manner in patients with advanced and heavily pretreated pancreatic adenocarcinoma are also shown. RESULTS: In vitro data showed the DAN-G cells did not show increased responses to gemcitabine with or without carboplatinum under hyperthermic culture conditions at 39 and 41.8 degrees C. Only temperatures of 43 degrees C led to increased hyperthermic damage. Clinical data showed that a therapy of whole-body hyperthermia at 41.8 degrees C with gemcitabine and carboplatin was well tolerated leading mainly to the expected hematological side-effects due to chemotherapy. The median overall survival after whole-body-hyperthemia was of 357 days, with a median progression-free survival of 140 days. CONCLUSION: Preclinical data indicate that hyperthermia does not increase the chemosensitivity of DAN-G pancreatic carcinoma cells to gemcitabine and carboplatin. Clinical data show that a treatment of pancreatic adenocarcinoma with C whole-body hyperthermia at 41.8 degrees with gemcitabine and carboplatin is feasible for patients with advanced disease. |
Authors:
|
Afsaneh Bakshandeh-Bath; Anne S Stoltz; Nils Homann; Thomas Wagner; Stephanie Stölting; Stefan O Peters |
Related Documents
:
|
10201518 - Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment o... 14659038 - Therapy of advanced non-small-cell lung cancer with irinotecan and gemcitabine in combi... 15969988 - Preoperative concomitant hyperfractionated radiotherapy and gemcitabine for locally adv... 14506598 - New perspectives in the management of pancreas cancer. 7569018 - Prognostic factors in patients with cervix cancer treated by radiation therapy: results... 21354598 - Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphade... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Anticancer research Volume: 29 ISSN: 1791-7530 ISO Abbreviation: Anticancer Res. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-08-07 Completed Date: 2009-09-30 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 3069-77 Citation Subset: IM |
Affiliation:
|
Division of Hematology, Medical Department I, Medical University of Schleswig-Holstein-Luebeck, Luebeck, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
secondary,
therapy* Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Carboplatin / administration & dosage Cell Cycle / drug effects Combined Modality Therapy Deoxycytidine / administration & dosage, analogs & derivatives Female Humans Hyperthermia, Induced* Liver Neoplasms / secondary, therapy* Male Middle Aged Neoplasm Staging Pancreatic Neoplasms / pathology, therapy* Pilot Projects Prognosis Survival Rate Treatment Outcome Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
41575-94-4/Carboplatin; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mutation of ameloblastin gene in calcifying epithelial odontogenic tumor.
Next Document: Tumor-specific cytotoxic activity of 1,2,3,4-tetrahydroisoquinoline derivatives against human oral s...